Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPA3 | P15088 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 5/20 | 0.47 |
| ▸ | ANPEP | P15144 | 3/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43394 | 1.00 | CPA1 (0.55) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL3495957 | 1.00 | CPA1 (0.55) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL10657726 | 0.85 | CPA1 (0.58) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL7276908 | 0.85 | CPA1 (0.58) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL7322202 | 0.85 | CPA1 (0.58) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL197907 | 0.82 | EPHX1 (0.64) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL287736 | 0.82 | EPHX1 (0.64) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL123055 | 0.82 | EPHX1 (0.64) | CPA1CPB1CPA3CPB2SLC15A1 | |
| SCHEMBL10433814 | 0.82 | CSNK1E (0.58) | CPA3SLC15A1ALPIPKMPTGS1 | |
| SCHEMBL6425554 | 0.82 | EPHX1 (0.62) | SLC15A1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | CPA1 3497/4885CPB1 2469/4885CPA3 2360/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CPA1 3497/4885CPB1 2469/4885CPA3 2360/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CPA1 3497/4885CPB1 2469/4885CPA3 2360/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CPA1 3497/4885CPB1 2469/4885CPA3 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.